Current druggable targets for therapeutic control of Alzheimer's disease

被引:31
作者
Gupta, Girdhari Lal [1 ,2 ]
Samant, Nikita Patil [2 ]
机构
[1] SVKMS NMIMS, Sch Pharm & Technol Management, Shirpur Campus, Shirpur 425405, Maharashtra, India
[2] SVKMS NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Ma, VL Mehta Rd, Mumbai 400056, Maharashtra, India
关键词
Clinical trial; Current therapy; Alzheimer's disease; GAMMA-SECRETASE INHIBITORS; AMYLOID-BETA; NEUROTROPHIC-FACTOR; TRANSGENIC MOUSE; AXONAL-TRANSPORT; TAU AGGREGATION; DIETARY-INTAKE; PHASE-3; TRIAL; A-BETA; RISK;
D O I
10.1016/j.cct.2021.106549
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Alzheimer's disease (AD) is a neurodegenerative brain disorder that has an increasingly large burden on health and social care systems. The pathophysiology involves the accumulation of extracellular amyloid-beta plaques (A beta) and intracellular neurofibrillary tangles contributing to neuronal death and leading to cognition impairment. However, its cause remains poorly understood, and there is no cure for AD despite extensive research and billions of dollars spent over decades. Currently, there are only four US Food and Drug Administration (FDA) approved drugs and one combination therapy available in the market for the symptomatic relief of AD. Since 2003, no new drug has been approved by the FDA for the treatment of AD. Researchers continue to explore new treatments and therapeutic strategies to treat AD. The need for novel discoveries on therapeutic targets and the development of new therapeutic approaches is imminent when considering the current expectations regarding the increased number of AD cases each year and the huge financial cost amounted to healthcare. This review focused on the current status of drugs in the clinical pipeline targeting beta-amyloid, tau phosphorylation, or neurotransmitter dysfunction for therapeutic control of Alzheimer's disease.
引用
收藏
页数:12
相关论文
共 112 条
[1]  
Abushakra S, 2016, J Prev Alzheimers Dis, V3, P219, DOI 10.14283/jpad.2016.115
[2]  
Alzheimer's Association, 2016, Alzheimers Dement, V12, P459
[3]   2020 Alzheimer's disease facts and figures [J].
不详 .
ALZHEIMERS & DEMENTIA, 2020, 16 (03) :391-460
[4]   Cyclin dependent kinase 5: A novel avenue for Alzheimer's disease [J].
Bhounsule, Anisha S. ;
Bhatt, Lokesh Kumar ;
Prabhavalkar, Kedar S. ;
Oza, Manisha .
BRAIN RESEARCH BULLETIN, 2017, 132 :28-38
[5]   The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer's disease and related tauopathies [J].
Brunden, Kurt R. ;
Yao, Yuemang ;
Potuzak, Justin S. ;
Ferrer, Nuria Ibarz ;
Ballatore, Carlo ;
James, Michael J. ;
Hogan, Anne-Marie L. ;
Trojanowski, John Q. ;
Smith, Amos B., III ;
Lee, Virginia M. -Y. .
PHARMACOLOGICAL RESEARCH, 2011, 63 (04) :341-351
[6]   Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy [J].
Brunden, Kurt R. ;
Zhang, Bin ;
Carroll, Jenna ;
Yao, Yuemang ;
Potuzak, Justin S. ;
Hogan, Anne-Marie L. ;
Iba, Michiyo ;
James, Michael J. ;
Xie, Sharon X. ;
Ballatore, Carlo ;
Smith, Amos B., III ;
Lee, Virginia M. -Y. ;
Trojanowski, John Q. .
JOURNAL OF NEUROSCIENCE, 2010, 30 (41) :13861-13866
[7]   Amyloid β-Induced Nerve Growth Factor Dysmetabolism in Alzheimer Disease [J].
Bruno, Martin A. ;
Leon, Wanda C. ;
Fragoso, Gabriela ;
Mushynski, Walter E. ;
Almazan, Guillermina ;
Cuello, A. Claudio .
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2009, 68 (08) :857-869
[8]   Progress and Developments in Tau Aggregation Inhibitors for Alzheimer Disease [J].
Bulic, Bruno ;
Pickhardt, Marcus ;
Mandelkow, Eckhard .
JOURNAL OF MEDICINAL CHEMISTRY, 2013, 56 (11) :4135-4155
[9]   The potential protective effect of tramiprosate (homotaurine) against Alzheimer's disease: a review [J].
Caltagirone, Carlo ;
Ferrannini, Luigi ;
Marchionni, Niccolo ;
Nappi, Giuseppe ;
Scapagnini, Giovanni ;
Trabucchi, Marco .
AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2012, 24 (06) :580-587
[10]   Enhanced GABAA receptor-mediated activity following activation of NMDA receptors in Cajal-Retzius cells in the developing mouse neocortex [J].
Chan, CH ;
Yeh, HH .
JOURNAL OF PHYSIOLOGY-LONDON, 2003, 550 (01) :103-111